Skip to main content

MRSN

Stock
Health Care
Biotechnology

Performance overview

MRSN Price
Price Chart

Forward-looking statistics

Beta
1.96
Risk
100.00%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.

Company info

SectorHealth Care
IndustryBiotechnology
Employees189
Market cap$261.9M

Fundamentals

Enterprise value-$40.8M
Revenue$34.0M
Revenue per employee
Profit margin-217.63%
Debt to equity-0.80

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$0.59
Dividend per share
Revenue per share$0.28
Avg trading volume (30 day)$972K
Avg trading volume (10 day)$1M
Put-call ratio

Macro factor sensitivity

Growth+1.7
Credit+5.0
Liquidity-1.9
Inflation-1.9
Commodities+1.0
Interest Rates-1.8

Valuation

Dividend yield0.00%
PEG Ratio-0.41
Price to sales1.06
P/E Ratio-0.41
Enterprise Value to Revenue-1.20
Price to book-1.17

Upcoming events

Next earnings dayMay 15, 2025
Next dividend day
Ex. dividend day

News

Mersana Therapeutics, Inc. (MRSN) Reports Q1 Loss, Lags Revenue Estimates

Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.19 per share versus the Zacks Consensus Estimate of a loss of $0.21. This compares to loss of $0.16 per share a year ago.

Zacks Investment Research (May 15, 2025)
Why Is Cancer-Focused Mersana Therapeutics Stock Trading Lower On Friday?

On Friday, Mersana Therapeutics Inc. MRSN released initial data from the Phase 1 dose escalation and backfill cohorts for emiltatug ledadotin.

Benzinga (January 10, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free